We are pleased to announce that we have funded the creation and maintenance of the FOSTER consortium website. In the last 30 years there has been little change to osteosarcoma treatment or survival. We now have an opportunity to change this through the FOSTER (Fight...

Rare primary malignant bone sarcoma (RPMBS) is a term for rare bone cancers, and they account for no more than a tenth of fast-growing bone tumours. It can be difficult to research RPMBS as they are so rare. This slows down the development of new treatments. RPMBS...

We were delighted to award Dr Tanya Heim a travel grant to present her work at FACTOR. Find out more about her work and FACTOR in her guest blog post. I have been a biomedical research scientist for over a decade. I have not always studied cancer, but I have always...

Making it better for young people with Osteosarcoma is the mission of MIB Agents. Every year they bring together patients, families, doctors and researchers to drive forward research into bone cancer. This June the conference, called FACTOR, took place in Atlanta and...

We were delighted to award Dr Wolfgang Paster a travel grant to present his work at the 20th Annual Meeting of CancerA disease where cells divide and grow uncontrollably and can spread to other areas of the body. Immunotherapy earlier this year. Find out more about his work in his guest blog post.

Every year cancer experts from across the world come together for The American Society of Clinical Oncology Annual Meeting (ASCO). The aim of ASCO is to share knowledge and provide updates on cancer research. By working together we hope to develop new cancer...

The British Sarcoma Group (BSG) annual conference took place on March 22nd – 23rd 2023 in Newport, Wales. We were delighted to attend as an exhibitor to promote our Osteosarcoma Now Trial Explorer (ONTEX) and our 2023 grant funding round. It was also inspiring to hear...

Researchers have developed a new drug that works against bone cancer. The drug, called CADD522, has shown promising results in the laboratory.

A clinical trial in the USA is recruiting patients with osteosarcoma and other cancers to test a new drug complex called GD2 SADA: 177 Lu DOTA. This drug uses a new technology where it can disassemble and reassemble itself. By changing the way it’s constructed it can...

A clinical trial has opened in Poland that will test whether regorafenib can be used to treat bone cancers. We interviewed trial lead Professor Raciborsk.